- Lexaria
Bioscience has its innovative DehydraTECH drug delivery platform
- The
company’s DehydraTECH technology is complementary to other R&D being
done on cannabinoids
- Lexaria
recently attended O’Cannabiz 2018 in Vancouver
A biotech company, Lexaria Bioscience Corp. (CSE: LXX)
(OTCQX: LXRP) offers a unique platform that makes it possible to deliver
bioactive substances through oral ingestion. Its DehydraTECH technology
accomplishes this without the need for unhealthy inhalational dosing.
DehydraTECH uses only GRAS (Generally Recognized as Safe) ingredients and
increases bio-absorption by five to 10 times. Based in Kelowna, British
Columbia, Lexaria Bioscience is the only company globally with patents issued
for the oral delivery of all cannabinoids.
The DehydraTECH drug delivery platform encapsulates
cannabinoid compounds in a lipid molecule to eliminate undesirable tastes in
cannabinoid edibles. Moreover, this improves bioavailability by protecting the
cannabinoid compounds from stomach and first-pass liver metabolism (http://ibn.fm/tyvvj). The
technology promotes lower overall dosing and higher effectiveness of lipophilic
active molecules.
Recently, Lexaria Bioscience Chief Executive Officer Chris
Bunka discussed company progress and plans at O’Cannabiz 2018 (http://ibn.fm/5uF6B). The
O’Cannabiz Conference and Expo took place in Vancouver, British Columbia, in
December 2018. The conference featured hundreds of international cannabis
companies. Bunka noted (http://ibn.fm/ziUJo)
that, in a nutshell, Lexaria makes, “…cannabis products taste better, smell
better, and get into your bloodstream a lot more quickly.”
Lexaria Bioscience has provided these benefits to tea and
other products. The company removes unwanted tastes as well as smells.
Therefore, there is no need to add a lot of sugars or artificial ingredients to
mask unpleasant flavors. Lexaria’s tea products sell as ViPova branded premium
teas. The company’s other products include TurboCBD high-absorption, full
spectrum hemp oil capsules.
Bunka further noted that Lexaria Bioscience has 10 patents
granted with over 50 patents pending. Four of the granted patents focus on the
delivery of nicotine. The company is not partnering with the tobacco industry.
However, Bunka informed that Lexaria is exploring the potential use of its
DehydraTECH technology to help people stop smoking.
The company’s technology has been shown to deliver nicotine
to the brain quicker than traditional delivery systems. The goal for Lexaria is
to put nicotine into some type of oral form to eliminate the need for
inhalation and help people curb their smoking habits. DehydraTECH studies in
2018 included two animal studies that delivered pioneering results highlighting
the improvements of nicotine delivery to blood plasma and across the blood-brain
barrier (http://ibn.fm/QOjnR).
Lexaria Bioscience’s technology is patent protected for
cannabidiol and all other non-psychoactive cannabinoids. The company has
patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs),
nicotine, other psychoactive cannabinoids and other molecules. An enabling
technology and not a competing one, DehydraTECH is a complementary layer that
works with the other research and development (R&D) being done on cannabinoids.
Lexaria Bioscience is on the move in its industry. The
company is hiring new personnel and building a new laboratory in Canada. It
recently created four new subsidiaries, which it is staffing up as well. With
more growth on the horizon, Lexaria offers potential profit opportunities to
investors wanting to leverage the company’s innovative DehydraTECH drug
delivery platform.
For more information, visit the company’s website at www.LexariaBioscience.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment